Compare Cytokinetics Inc (CYTK) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Williams Companies Inc — how do they compare? Cytokinetics Inc trades at $62.73 (market cap $8.62B), while Williams Companies Inc trades at $73 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 10.3× Cytokinetics Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Williams Companies Inc for 58 Days on average.
| CYTK | WMB | |
|---|---|---|
Market Cap | $8.62B | $88.48B |
Volume | 2,594,626 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $87.26 | $79.40 |
52-Week Low | $54.76 | $56.51 |
Typical Hold Time | 19 Days | 58 Days |
Enterprise Value | $8.72B | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Williams Companies (WMB) trades at $71.46, down 1.28% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with 25.18% net income margin and 24.02% ROE, though recent earnings have been mixed with two misses and one beat. Analyst consensus is strongly bullish with 79% buy ratings and an $87.27 price target, representing 22% upside. Recent news highlights WMB's positioning to benefit from AI-driven natural gas demand growth.
WMB offers compelling value with strong cash flow generation and dividend growth potential, though investors face risks from energy market volatility and high debt levels. The company's fee-based revenue model provides stability, while strategic acquisitions like Momentum Midstream enhance growth prospects. Current valuation at 28.82 P/E appears reasonable given the growth trajectory and defensive characteristics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
